Midcap pharma stocks are attractive: Sudip Bandyopadhyay

Sudip Bandyopadhyay, Managing Director & CEO, Convexity Solutions in an interview with ET Now talks about midcap pharma stocks.

What is your call on the pharmaceutical space right now especially midcap pharma?

I like midcap pharma quite a lot in fact if you look at the pharmaceutical industry there is whole lot of things which have happened in the past 6 to 12 months. The entire international market has been looking at the Indian pharma particularly the midcap pharma with a great interest not only the M&A.

Of course there are M&As happening and I think there is a whole lot of potential M&As being discussed at various stages which definitely makes it attractive as a pick. Apart from that I think international pharma majors are looking at India as a manufacturing base for their products and that presents a great interesting opportunity for midcap Indian pharma so these two things apart from the new markets which some of these pharma companies are exploring particularly in the non-developed side which is the African markets make midcap pharma an interesting area but one has to be careful as to which companies you are picking.

We like Ipca Laboratories quite a bit and there are other companies also like Ipca which can give an excellent return from current levels.